Skip to search formSkip to main contentSkip to account menu

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in… 
Highly Cited
2010
Highly Cited
2010
From the Departments of Immunology,* Histology and Embryology, and Pathology, Center of Biostructure Research, Medical University… 
Review
2009
Review
2009
Bortezomib (VELCADE) is a proteasome inhibitor that not only targets the myeloma cell, but also acts in the bone marrow micro… 
Highly Cited
2005
Highly Cited
2005
Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in… 
Highly Cited
2005
Highly Cited
2005
Bortezomib (formerly PS‐341) has significant activity in patients with relapsed multiple myeloma (MM), its efficacy is increased… 
Highly Cited
2005
Highly Cited
2005
The prompt response to bortezomib observed in a 63‐year‐old woman with multiple myeloma was associated with a significant…